Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation.

Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, Bradner JE, Tolliday N, Stegmaier K.

Chem Biol. 2013 May 23;20(5):713-25. doi: 10.1016/j.chembiol.2013.03.020.

2.

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA.

Clin Cancer Res. 2015 May 15;21(10):2348-58. doi: 10.1158/1078-0432.CCR-14-1290. Epub 2015 Feb 16.

3.

Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.

Pinkerneil M, Hoffmann MJ, Deenen R, Köhrer K, Arent T, Schulz WA, Niegisch G.

Mol Cancer Ther. 2016 Feb;15(2):299-312. doi: 10.1158/1535-7163.MCT-15-0618. Epub 2016 Jan 15.

4.

A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.

Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, Barozzi I, Senese S, Fornasari L, Moretti S, Altucci L, Pelicci PG, Chiocca S, Johnstone RW, Minucci S.

Blood. 2013 Apr 25;121(17):3459-68. doi: 10.1182/blood-2012-10-461988. Epub 2013 Feb 25.

5.

HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.

Buurman R, Sandbothe M, Schlegelberger B, Skawran B.

Eur J Med Res. 2016 Jun 24;21(1):26. doi: 10.1186/s40001-016-0217-x.

6.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Min C, Moore N, Shearstone JR, Quayle SN, Huang P, van Duzer JH, Jarpe MB, Jones SS, Yang M.

PLoS One. 2017 Jan 6;12(1):e0169128. doi: 10.1371/journal.pone.0169128. eCollection 2017.

7.

Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement.

Paino F, La Noce M, Tirino V, Naddeo P, Desiderio V, Pirozzi G, De Rosa A, Laino L, Altucci L, Papaccio G.

Stem Cells. 2014 Jan;32(1):279-89. doi: 10.1002/stem.1544.

8.

Selective HDAC inhibition for the disruption of latent HIV-1 infection.

Barton KM, Archin NM, Keedy KS, Espeseth AS, Zhang YL, Gale J, Wagner FF, Holson EB, Margolis DM.

PLoS One. 2014 Aug 19;9(8):e102684. doi: 10.1371/journal.pone.0102684. eCollection 2014.

9.

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

Stojanovic N, Hassan Z, Wirth M, Wenzel P, Beyer M, Schäfer C, Brand P, Kroemer A, Stauber RH, Schmid RM, Arlt A, Sellmer A, Mahboobi S, Rad R, Reichert M, Saur D, Krämer OH, Schneider G.

Oncogene. 2017 Mar 30;36(13):1804-1815. doi: 10.1038/onc.2016.344. Epub 2016 Oct 10.

PMID:
27721407
10.

Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.

Lund RJ, Emani MR, Barbaric I, Kivinen V, Jones M, Baker D, Gokhale P, Nykter M, Lahesmaa R, Andrews PW.

Stem Cell Res. 2013 Nov;11(3):1022-36. doi: 10.1016/j.scr.2013.07.002. Epub 2013 Jul 18.

11.

Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins.

Pang M, Ma L, Liu N, Ponnusamy M, Zhao TC, Yan H, Zhuang S.

J Cell Biochem. 2011 Aug;112(8):2138-48. doi: 10.1002/jcb.23135.

12.

Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.

Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL.

Am J Hematol. 2015 Jul;90(7):624-8. doi: 10.1002/ajh.24019. Epub 2015 May 28.

13.

HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.

Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, McDowell ME, Wellman H, Tyler JK, Cairns BR, Chandrasekharan MB, Bhaskara S.

Oncotarget. 2015 Mar 10;6(7):4863-87.

14.

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, Kung AL, Golub TR, Stegmaier K.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9751-6. doi: 10.1073/pnas.0710413105. Epub 2008 Jul 7.

15.

Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.

Durham BS, Grigg R, Wood IC.

J Neurochem. 2017 Oct;143(2):214-224. doi: 10.1111/jnc.14144.

PMID:
28796285
16.

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.

Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL.

Br J Pharmacol. 2008 Feb;153(4):657-68. Epub 2007 Dec 3.

17.

Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.

Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L, Seiser C.

Cell Cycle. 2011 Feb 1;10(3):406-12. Epub 2011 Feb 1.

18.

Redundant control of adipogenesis by histone deacetylases 1 and 2.

Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN.

J Biol Chem. 2010 May 7;285(19):14663-70. doi: 10.1074/jbc.M109.081679. Epub 2010 Feb 26.

19.

Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2.

Icardi L, Lievens S, Mori R, Piessevaux J, De Cauwer L, De Bosscher K, Tavernier J.

FASEB J. 2012 Jan;26(1):240-9. doi: 10.1096/fj.11-191122. Epub 2011 Sep 28.

PMID:
21957129
20.

CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.

Yang PM, Lin PJ, Chen CC.

Epigenetics. 2012 Apr;7(4):390-9. doi: 10.4161/epi.19373. Epub 2012 Apr 1.

Supplemental Content

Support Center